PULSE 2019 - Speaker Biographies
Barbara has worked in the life sciences industry for thirty years, with the first eleven years on the commercial side of a large organisation (ICI/Zeneca/AstraZeneca), after which she transitioned to the entrepreneurial world of biotech and emerging companies.
At Autifony, Barbara is responsible for strategic partnering and preparation for commercialisation of pioneering new drugs to treat schizophrenia and other serious CNS disorders. Until recently, Barbara was also Chair of Puridify, a UCL spin-out with whom she had been involved since the beginning and which was acquired by GE in November 2017. She is Chair of the LifeArc Seed Fund Investment Committee. Barbara is also a member of the Cambridge Enterprise Seed Fund Investment Committee, and Non-Executive Director of Yaqrit, another UCL spin-out which focuses on new liver disease treatments,
Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-Residence on a part time basis, where she uses her experience of building early stage companies and her extensive network across pharma, biotech and academia to help support Translation activities.
Previously, Barbara was CEO of Stabilitech for over four years where she raised funding, established twelve commercial collaborations and built the team from early stage. Before that Barbara was Commercial Director at Arrow Therapeutics, until the company was acquired by AstraZeneca.
Charlotte believes in equitable access to effective therapies. She is the CEO and Co-founder of Theolytics - a pre-clinical biotech company harnessing viruses to fight cancer - and a Board Member of the UK Bioindustry Association. Previously Director of New Medicine Partners, Charlotte has worked with organisations spanning three continents to translate novel life science technologies to the point of commercial viability. She graduated as a University of Cambridge Bioscience Enterprise M.Phil Scholar and was a shortlisted finalist for Cambridge Entrepreneur of the Year. She was the youngest listed 2016 nominee for MT’s 35 under 35 Award.
Founder and co-director of Deep Science Ventures, Dominic launched his start-up and social enterprise consultancy whilst still at university. He's advised more than 100 early stage science based companies at Imperial College London and leads at Imperial Innovations on pre-acceleration and community development, now over 3000 scientists.
Dr Nicola Baker-Munton
Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem IPM. She is a Chartered UK Patent Attorney and European Patent Attorney with a joint honours degree in biology and biochemistry. During her nine years as an industrial practitioner at the Wellcome Foundation Limited, and four years in the private sector, Nicola recognised the need for much greater assistance with management of intellectual property earlier in the development of technologies, and advice and assistance with commercialisation throughout the technology/product life-cycle.
Nicola founded Stratagem IPM in 1999. With Steady growth it has become the leading specialist company providing active strategic management of intellectual property portfolios from inception through development to market, and from academia through startup to stock market listing.
David Roberts B.Sc (Hons), LLB (Hons)
Kath Mackay is interim Director of Ageing Society, Health & Nutrition at Innovate UK. Kath leads a team working to grow and scale the best UK businesses developing biomedical, health, agriculture and food innovations.
Kath joined Innovate UK in 2013 to co-manage the Regenerative Medicine & Advanced Therapies Programme, working to support the growing UK cell and gene therapy industry and growing market confidence to make the sector more investable. In doing this Kath worked closely with the Cell and Gene Therapy Catapult, and latterly she has led establishment of the Medicines Discovery Catapult for Innovate UK.
She has also held the roles of Head of Precision and Discovery Medicine and Deputy Director of Ageing Society, Health & Nutrition.
Kath has a PhD in pharmacology where she researched using stem cell models for novel drug discovery applications. Prior to joining Innovate UK she held commercial biotech roles providing experience of the life sciences industry in the UK and the USA.
Dr Terry O’Neill is the Head of Health at KTN Ltd. Previous roles include Industry Sector Manager at TWI Ltd with responsibility for the medical sector. Before TWI Terry worked as a business development manager at the Norwich based technology transfer and intellectual property development company PBL. He has a background in project management in the biotechnology industry. Terry was a member of the Management Team at the physics start-up company Antenova where he managed the process of raising over £6m worth of private equity during the companies’ series B funding round. Terry has also worked in the NHS.
Within the KTN Terry is the Head of Health responsible for managing the Health Team with priority activities in medicines development and manufacture, medical technologies and digital health.
Oliver works exclusively with Life Science companies and manages the Life Science Tax team at FTI Consulting.
Latterly Oliver worked in industry where he was responsible for all taxes across the EMEA region for a multinational US listed group.
Prior to that, Oliver spent ten years with PwC, working across a number of tax areas including Corporate Tax, Employment Taxes and the Tax Technical knowledge team.
Oliver Support life sciences clients in R&D incentive claims for large enterprises and SMEs and related transactional advice and planning. He also advises on licensing of intellectual property rights and Patent Box elections in regards to optimal timing and the potential benefits.
Oliver holds a BSc in Biochemistry from Imperial College, London and is an Associate of the Royal College of Science.
A corporate finance lawyer, Charles has extensive experience in advising on a range of financings, IPOs, mergers and acquisitions and joint ventures in London, Warsaw and Hong Kong. His primary focus is advising clients in the biotech, medtech and pharma sectors on venture capital financing, IPOs, mergers and acquisitions and other corporate transactions. He is regularly ranked in Chambers and Legal 500 and is described as 'very, very good and has a familiarity with the [life sciences] sector which meant we could dispense with the niceties and get down to business'.
Dr Harren Jhoti
Harren Jhoti co-founded Astex in 1999 and was Chief Scientific Officer until November 2007 when he was appointed Chief Executive Officer. He was elected a Fellow of the Royal Society in 2018, the Royal Society of Chemistry in 2016, and of the Academy of Medical Sciences in 2015. In January 2018 he was honoured with a Lifetime Achievement Award from the UK BioIndustry Association (BIA). He received the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery from the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007.
Dr. Jhoti has published widely including in leading journals such as Nature and Science, and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. He has served on the board of the BIA, the UK BioIndustry Association and currently consults for life science venture capital firms. Before founding Astex in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.
Heather is a post graduate who has worked as an HR practitioner for over 20 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech where she seems to have found her home. Key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions have helped her develop an understanding of the specific challenges of our industry; and learn to develop solutions to these involving talent attraction, engagement, recognition and development. She has relocated to both San Francisco and Switzerland to give her a better understanding of diverse cultures and best working practices throughout her Pharma years.
Her journey in Biotech started in 2015 when she joined Horizon Discovery, and learnt to move faster, work more creatively and with a focus on cost, and is proud to lead an organisation’s total talent strategy. Her mission is to create imaginative and diverse solutions that fit the uniqueness of Horizon; avoid creating an internal HR industry; and ensure that Horizon’s culture continues to focus on its diversity to deliver the same exciting future for its people, that its science creates for its customers.
Sarah Shackelton, Partner, Marketing & Talent, at Abingworth has more than 20 years of experience working with life sciences companies to build their boards and senior leadership teams. Recently, she chaired the Nominations Committee of Wilson Therapeutics and helped recruit the senior executives and board directors for Nouscom, Verona Pharma and Virion Biotherapeutics. Sarah also markets Abingworth to pharmaceutical and biotechnology companies, expanding its network of key industry executives and entrepreneurs.
Sarah joined Abingworth after managing senior level searches for healthcare and private equity clients, as well as venture capital firms and their portfolio companies, at global executive search firms. Previously, she worked with the pharmaceutical industry as a US trade negotiator and consultant and with the European Bank for Reconstruction and Development, in a marketing capacity. She has a BA in International Relations from Pomona College, California, and an MA in Public Affairs from Princeton University.
Dr Claire Button is Founder of FUSION Biomed, a specialist search and investment partner for early stage, high-growth life science and healthtech companies.
With a passion for life science founded on a first degree in Medical Biochemistry and a PhD in Immunopharmacology, Claire has specialised in life science executive search since 2008.
She brings extensive sector knowledge and commercial understanding, combined with a global network to introduce her clients to high-demand leaders ahead of their competitors.
Claire founded FUSION Biomed to share the excitement and manage the risks of early stage companies with her clients.
Claire heads up FUSION Biomeds’ programme of events to support early-stage companies as well as our initiatives to promote diversity. She regularly presents at external events supporting early stage companies and diversity. Claire is a leader in the field of building out first teams in early stage ventures.
In her 26 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
She is one of five Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund (with greater than $2 billion in total assets) for life sciences investing in US and Europe. Kate is responsible for biotech investments and activities in the EU and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. These investments include small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas.
Kate played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.
Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.
Kate won the Lifetime Achievement Award, presented by BioIndustry Association UK in January 2017. Kate also serves on the Board of the Francis Crick Institute, serves as Deputy Chairman of St Paul’s Girls’ School, London, and sits on the Investment Committee of Oxford University Spin-out Equity Management (OSEM).
Dominic is a Partner of Syncona Investment Management Ltd. Prior to joining Syncona, he was a member of the life science team at strategy consultancy L.E.K. Consulting. Dominic received his Ph.D. from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics. His research has been honoured with national and international prizes and published in Cell, Nature and Science.
Oliver Sexton joined Midven in April 2014 to manage the UK Innovation & Science Seed Fund’s synthetic biology investments.
Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.
Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.
Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.
Pam Garside has her own management consultancy, Newhealth, specialising in organisational strategy and development in health care, and is a Fellow of the Judge Business School of the University of Cambridge. She advises new entrants to the UK health market including digital and start up companies and is an angel investor.
Pam founded and co-chairs The Cambridge Health Network, a membership group of senior players in UK health,both private and public sector. She sits on the Investment Committee of Cambridge Enterprise, the technology transfer company of the University of Cambridge and is a member of Cambridge Angels.She is a board member of Whizz-Kidz charity, ZPB Ltd and a senior adviser to Smith Square Partners. In 2016 Pam was named one of the 100 most influential leaders in Health Tech by Hot Topics.
Pam began her professional life in management in the NHS and subsequently spent many years studying and working internationally based in the USA. She holds a BSc from the University of Durham and a Masters Degree in Hospital and Health Care Administration from the University of Minnesota. She is an Adjunct Professor at Imperial College Business School.
Jeanne joined Johnson & Johnson Development Corporation (JJDC) as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.
In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.
Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Houman Ashrafian is a parallel entrepreneur and company builder. He joined SV in 2016. Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolicssuccessfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation.Houman went on to become Vice President and head of the Clinical Science Group at UCB. Pharma before becoming an SV Venture Partner.Academic credentialsUndergraduate degree, University of Cambridge; BM BCh, DPhil, University of OxfordOutside of SVFollowing completion of his cardiology training, Houman was appointed as anHonorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and head of Experimental Therapeutics at the University of Oxford.He is cofounder and Chairman of Weatherden, a boutique clinical development company, and cofounder of Cinpovium.
Dr Ayokunmi Ajetunmobi
As Venture Development Manager at BioCity, Dr Ayokunmi Ajetunmobi works with scientific founders and clinical entrepreneurs to build venture-backed businesses solving the biggest health and environmental challenges.
He previously led the next-generation sequencing division at Desktop Genetics, a VC-backed startup partnered with Illumina, where he negotiated projects with global biopharma clients that led to successful regulatory filings of genome-edited CAR-T cell therapies. This activity contributed to the acquisition of Desktop Genetics.
Other roles have included business development for OneStart, a global biotech and healthcare startup accelerator, and co-founder of Evolve Biomed, a national biomedical innovation conference. His academic qualifications include a bachelor’s in neuroscience, master’s in molecular medicine and doctorate in clinical medicine.
Dr. Rowley joins BioScience Managers from IP Group where, since 2013, she was a Director, responsible for sourcing investment opportunities, due diligence and management of investment deals for IP Group’s healthcare portfolio. She evaluated and helped to secure a number of significant investments in portfolio companies and, in addition, led and closed M&A deals with external investors and advisors. She represented the interests of IP Group on the Boards of five portfolio companies as an Investment Director and completed several secondments within portfolio businesses in CEO and Business Development roles.
Before joining IP Group Dr. Rowley held a number of roles at Quotient Clinical, now Quotient Sciences and several positions in Business Development, including at Nexxus, the West of Scotland Bioscience Network.
Prior to her career in business, Dr. Rowley was the Honorary Research Fellow of Glasgow University, where she managed a team to successfully develop and implement independent research projects. She has a first class B. Sc. (Hons.) degree in Applied Microbiology and Biotechnology from the University of Sunderland, a Ph.D. in Molecular Virology from the University of Reading and a Masters in Business Administration from the University of Glasgow.
Rick is Senior Director, New Ventures and Transactions, Oncology at Johnson & Johnson Innovation, London . In this role, Rick leverages his experience and knowledge of the scientific and biotech landscape to identify and evaluate external opportunities and deliver transformative innovation into the pipeline.
Rick has over 17 years of experience in the life sciences sector. Before joining Johnson & Johnson he was the Chief Executive Officer of a European clinical stage biotech company, Trino Therapeutics. Previously, he held a number of key positions at the Wellcome Trust. He was responsible for maximising financial returns on direct healthcare investments in both private and public equities and venture capital funds in their Investment Division. During this time he was on the board of directors of a number of biotech companies and worked closely with management teams on strategy, financing and exits via M&A and public listings.
Prior to this role, Rick was in Business Development where he established and managed a large corporate venture fund, building an extensive external pipeline of preclinical pharmaceutical assets sourced from EU and US academic and biotech labs. After a obtaining a PhD in pharmacology, he started his career in the biotechnology industry at Pharmagene where he helped to establish their therapeutics division and led multi-disciplinary teams in drug development and contract research.
Before co-founding GTN, Noor was an assistant professor at Aalborg University in Copenhagen working on machine learning with special interest in generative models. She has more than 50 publications and 1200+ citations. She has co-authored a book on generative methods and has won a number of grants and awards for her research. She served as the Chair of the IEEE Games Technical committee and co-organised task forces and conferences.
Thalita Marinho is a Director in the Strategy team of PricewaterhouseCoopers.
She has twelve years of industry and consulting experience in the pharmaceutical and energy sectors. She worked at Royal Dutch Shell in Strategy and Economic valuation roles. She also worked for Booz & Company, a strategic management consultancy, where she focused on strategic issues in the pharma and Life sciences sector.
At PwC Thalita assists clients developing corporate and business level strategy. She leads projects on topics across the pharma value chain, including Market Access & Pricing, Sale & Marketing and Patient Centricity. Her clients include Big Pharma, biotechs, generics, OTC and healthcare distributors.
Thalita has an MBA from the London Business School and is an Economist. She is fluent in English, Portuguese and Spanish
Dr Emma Stanton is CEO of Four Eyes Insight who are experts at finding clinical efficiency and building sustainable improvements to health care. Prior to this, Emma held various leadership roles at Beacon Health Options including as Chief Partnership Officer for Northeast USA, Associate Chief Medical Officer for Beacon in the USA and from 2011 - 2017, Emma was Founder and CEO of Beacon in the UK. From 2010 – 2011, Emma was a Commonwealth Fund Harkness Fellow in Health Care Policy and Practice, and is now a senior associate at the Institute for Strategy and Competitiveness, Harvard Business School, USA.
Nominated as one of HSJ’s most inspirational women in health and also one of the HSJ Top Innovators in the NHS, Emma holds an executive MBA from Imperial College, London, a MRCPsych from the Royal College of Psychiatrists and a BM from Southampton University. Emma’s publications include Clinical Leadership: Bridging the Divide (Quay Books, 2009) and MBA for Medics (Radcliffe, 2010).
David Holbrook is a qualified physician who has spent thirty-five years in medicine and medical innovation, and the last twenty in life sciences spinout investing, principally from academia. After senior business development roles in Glaxo and Roche he headed up Imperial College’s spinout activities, led the life science practice of UK venture capital manager MTI (who raised and managed a fund with The University of Manchester), and most recently was Director of Life Science Seed Funds at Cambridge University Enterprise. David holds degrees from King’s College London, Oxford University, and Harvard University.
Hitesh is a Partner of Syncona Investment Management Ltd. He has 24 years’ experience of global public equities. He managed Innovation funds for several asset management companies including Aviva and ADIA, where he was a top-rated portfolio manager. He has an interest in the convergence of life science with other innovation led sectors such as data sciences and the application of industrial technology in medical diagnostics. He has a degree in Chemistry from King’s College London and is a CFA.
Dr Andy Richards
Andy has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, and Cancer Research Technology (commercial arm of CR-UK. He is an advisor to Cambridge Innovation Capital and the UCL Technology Fund.
His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Ed is a Partner of Syncona Investment Management Ltd.
He is currently Executive Chairman of Syncona’s company OMass Therapeutics, and was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL). Within the Syncona life science team, he is involved in creation of new businesses and then fills executive roles within those companies to make them operational.
Prior to Syncona, he was CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). Ed’s early career was spent in research and management positions with Wyeth-Ayerst Inc and British Biotech. He holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.
Rebecca began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies, and went on to become Director, Healthcare Ventures at Imperial Innovations (now part of IP Group). Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA from Oxford University. She joined Longwall Ventures after a couple of years sabbatical break spent exploring South America in a VW camper van and focuses predominantly on medical technology opportunities.
Anthony is Executive Chairman at Eagle Genomics. As Chairman and CEO, he has built and exited a number of intellectual property rich B2B software companies. In particular, he was responsible for the turnaround, strategic repositioning and sale of private, venture backed communications software company, Psytechnics to US Nasdaq listed NetScout. As CEO, he was responsible for the turnaround, strategic repositioning and sale of Nasdaq and LSE listed network management software company, Orchestream plc. to US Nasdaq listed MetaSolv Software and as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle.
In addition to his extensive operational experience, Anthony has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies) and he is uniquely qualified in working with CEO’s and their management teams to meet the most significant challenges that they will encounter on their journey.
In addition to his responsibilities at Eagle Genomics, Anthony is chairman of the Supervisory Board of German headquartered nano-imaging company, JPK Instruments and is adviser to a number of B2B technology companies. He was most recently also active as a private equity investor.
Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses. Before joining Isogenica, Dr Sceats, was CEO of CN Bio Innovations, which she grew from a Oxford University spin-out to a recognised leader in human Organ-on-Chip technologies.
Dr Sceats was instrumental in the development and execution of CN Bio’s vision, resulting in strong revenue growth, rapid development of two innovative new products, and a pioneering partnership with the Food and Drug Administration to characterise the use of Organs-on-Chips in drug development and regulatory evaluation. Earlier in her career Emma was a technology manager at Oxford University Innovation, responsible for patenting, marketing and licensing technologies developed at the university and building spin-out companies to exploit IP.
Emma was a Presidential scholar in chemistry at the Massachusetts Institute of Technology and a graduate scholar at the University of Oxford (DPhil, Chemistry).
Laura is UK Director of Capital Cell, Europe’s first equity crowdfunding platform specialised in life sciences.
Capital Cell was established in Spain in 2015, and Laura joined in April 2016 to lead the set-up of the UK operation, starting with securing investment for the UK company through a self-funding round. Before joining Capital Cell Laura was a Research Fellow at Christ Church, Oxford in Molecular Evolutionary Genetics. She gained a PhD from Cambridge in the molecular evolution of butterfly wing pattern mimicry, and has a research Masters in cancer stem cell biology from Bristol University. She read Biology at Oxford as an undergraduate, and attained additional honours in the History and Philosophy of Science. During her Oxford fellowship Laura was exposed to entrepreneurship for the first time, and set out to find a role in which she could help as many amazing companies as possible get to market, and stay at the cutting edge of scientific innovation. Capital Cell fitted the bill.
As Director of the Alderley Park Accelerator, Ned is responsible for the strategic direction and leadership of the Accelerator, helping to build the ecosystem and cluster, supporting all aspects of company development from start-up to scale-up. Ned is also the founding director of an ophthalmic drug delivery company at Alderley Park, sits on the advisory board of Alderley Park Ventures, is on the General Committee of ELRIG, and has been significantly involved in the development of 7 start-ups. With proven sector expertise and awareness of market dynamics, he has been involved in excess of $500m of equity fund raisings for North American and European companies, which have a market value of over $2b today. Previously, Ned conducted primary research in neuropsychopharmacology, psychoneuroimmunology, and neuroscience at Yale Medical School and the University of Oxford.
Dr Fiona Kellas
Fiona is a UK and European Patent Attorney. Fiona graduated from the University of Glasgow with a degree in Biochemistry in 1998 and was awarded a PhD in Biochemistry from the University of Cambridge in 2003. During her PhD, Fiona carried out research in the MRC Laboratory of Molecular Biology and the MRC Mitochondrial Biology Unit in Cambridge. In addition to working in private practice, Fiona has experience of working in-house in the intellectual property department of an antibody technology company. Fiona has experience of drafting and prosecuting patent applications, preparing and filing design applications, as well as prior art and freedom to operate searching and assessment. Fiona has worked in a wide range of technologies. In particular, she has experience in the areas of biochemistry, antibody technology, industrial biotechnology, in vitro diagnostics, bioenergetics, synthetic biology and medical technologies and devices.
Dr Edward Rainsford
Edward is a UK and European Patent Attorney. Edward graduated from the University of Reading with a degree in Microbiology in 2000 and was awarded a PhD in Virology from the University of Warwick in 2006. Following his PhD, he moved to the United States where he worked as a Research Associate at the University of Virginia studying negative-strand RNA viruses replication. During his time as a research scientist he presented at a number of international conferences and published several research papers in virology journals. Edward has experience in patent drafting, patent prosecution, preparing and responding to infringement and validity opinions, preparing freedom to operate opinion, due diligence analysis, European Patent Office opposition proceedings, and UK and Community design applications.